Chitosans represent a group of multifunctional drug excipients. Here, we aimed to estimate the impact of high-molecular weight chitosan on the physicochemical properties of clotrimazole–chitosan solid mixtures (CL–CH), prepared by grinding and kneading methods. We characterised these formulas by infrared spectroscopy, differential scanning calorimetry, and powder X-ray diffractometry, and performed in vitro clotrimazole dissolution tests. Additionally, we examined the antifungal activity of clotrimazole–chitosan mixtures against clinical Candida isolates under neutral and acid conditions. The synergistic effect of clotrimazole and chitosan S combinations was observed in tests carried out at pH 4 on Candida glabrata strains. The inhibition of C. glabrata growth reached at least 90%, regardless of the drug/excipient weight ratio, and even at half of the minimal inhibitory concentrations of clotrimazole. Our results demonstrate that clotrimazole and high-molecular weight chitosan could be an effective combination in a topical antifungal formulation, as chitosan acts synergistically with clotrimazole against non-albicans candida strains.
30 September 2023 in Progress on Chemistry and application of Chitin and its Derivatives
This study evaluated hydrogels containing Celugel, 3% hop cone extract obtained from Humulus lupulus L. using supercritical carbon dioxide extraction substrate, and 1% and 2% chitosan for dermatological application to treat inflammatory skin conditions. The presence of chitosan significantly affected the rheological properties of the formulations, including their dynamic viscosity, hardness, consistency, cohesiveness, and blurring time. The formulations containing 2% chitosan showed the best application possibilities. The formulations were evaluated for dissolution of cohumulone, which is an analogue of humulone contained in hop cone extract. The concentration of chitosan in the formulations had a significant effect on the dissolution testing parameters of the active ingredient: as the chitosan concentration increased, the desired effect of prolonged release time of the active ingredient was achieved while maintaining the membrane-forming properties of Celugel.
Introduction: The official implementation of pharmaceutical-grade cannabis raw materials for medicinal use has permitted doctors to prescribe and pharmacists to prepare cannabis-based formulations. The objective of the pharmaceutical development and manufacturing process optimization work was to propose a suppository formulation containing doses of 25 mg and 50 mg of tetra-hydrocannabinol (∆-9-THC) as an alternative to existing inhalable or orally administered formulations. The formulation could be used for rectal or vaginal administration, thereby providing dosage control in the treatment of endometriosis and other conditions involving pain. In this study, two substrates from suppositories with standardized Cannabis extractum normatum (CEX) were used: cocoa butter and Witepsol® H15. Materials and Methods: The long-term stability of CEX was investigated over a period of up to 24 months. The concentrations of ∆-9-THC, cannabidiol (CBD), and cannabinol (CBN) were determined using an HPLC method. Furthermore, the water content of the extract, the ethanol residue, and the microbiological purity were determined. The pharmaceutical properties of CEX-incorporated suppositories, namely content uniformity, hardness, softening time, total deformation time, disintegration time, and the release profile of ∆-9-THC, CBD, and CBN, were evaluated in order to develop optimal preparation procedures for pharmacists. Results and Discussion: Following a 24-month stability study on CEX, no significant alterations in component content were observed beyond the specified requirements. The disintegration time, total deformation time, and hardness of the suppositories based on Witepsol® H15 with CEX were found to be longer and higher, respectively, than those of suppositories formulated with cocoa butter. In vitro studies demonstrated that suppositories prepared with Witepsol® H15 exhibited superior release of ∆-9-THC compared to those prepared with cocoa butter. Conclusions: We suggest that pharmacists making prescription drugs in a pharmacy setting in the form of medical marijuana suppositories will receive a better release profile of the drug by choosing Witepsol® H15 as a substrate.
Przedmiot badań: Konopie indyjskie były stosowane w medycynie od wieków. Historycznie rzecz biorąc, leki na bazie konopi były stosowane w leczeniu wielu schorzeń. W XX wieku nastąpiła penalizacja ich stosowania na świecie. Współcześnie wiele krajów dekryminalizuje ich stosowanie. Złożoność tematyki, zmienność jakościowa składników aktywnych poszczególnych odmian tego gatunku determinuje nowe obszary wymagające badania i analizy. Na uwagę zasługują kwestie prawne, problematyka kontroli jakości, niedobory randomizowanych i kontrolowanych badań klinicznych. Artykuł skierowany jest zarówno dla profesjonalistów związanych z opieką zdrowotną, jak i dla osób zainteresowanych zagadnieniami prawno-medycznymi oraz potencjalnymi korzyściami i wyzwaniami związanymi z konopiami medycznymi. Cel badań: W pracy przeanalizowano aspekty prawne i praktyczne dostępu do marihuany i jej stosowania do celów medycznych w Polsce. Materiał i metody: Analizy zagadnienia dokonano na podstawie aktualnego przeglądu piśmiennictwa. Porównanie rozwiązań i przeanalizowanie różnic w regulacjach prawnych marihuany stosowanej do celów medycznych w wybranych krajach umożliwi również wskazanie kierunków rozwoju w tym obszarze w Polsce. Wyniki: W niniejszej pracy omówiono ramy prawne dostępu do konopi medycznych i ich zastosowania do celów medycznych. W obrocie w Polsce znajduje się aktualnie co najmniej dwadzieścia jeden rodzajów surowców, które nawet przy zachowaniu tych samych poziomów THC (tetrahydrokannabinol) i CBD (kannabidiol), różnią się profilem terpenowym i tym samym szczegółowymi właściwościami terapeutycznymi, których znajomość może umożliwić farmaceutom wspieranie i monitorowanie farmakoterapii pacjentów w tym obszarze. Przestrzeń medycznego zastosowania konopi omówiona została także w aspekcie możliwości współpracy lekarzy i farmaceutów w ramach sprawowania usług na rzecz pacjenta celem osiągnięcia skuteczności terapeutycznej i wypracowania narzędzi zarządzania ryzykiem farmakoterapii konopiami medycznymi. Wnioski: W miarę łagodzenia ograniczeń w badaniach i stosowaniu, z pewnością zostaną znalezione nowe możliwości terapeutyczne. Tym samym pomimo licznych wyzwań związanych z zastosowaniem Cannabis jak problemy doboru surowca, kontroli jakości, stabilności, bezpieczeństwa i skuteczności, należy uznać za pozytywne dotychczasowe osiągnięcia, również o istotnym znaczeniu dla systemu opieki zdrowotnej w Polsce.
30 September 2022 in Progress on Chemistry and application of Chitin and its Derivatives
The aim of this paper was to formulate the composition of a bioadhesive film obtained based on acyclovir incorporated into natural bioadhesive polymers (chitosan and guar gum) in different quantitative ratios. To this end, the author developed a technology for preparing films containing various quantitative ratios of chitosan to guar gum: 1:0.25; 1:0.50; 1:0.75; 1:1; and 1.2:0.50. The formulations were used to prepare mucoadhesive films containing 2% acyclovir. The dressings were tested with respect to their physicochemical properties and subjected to dissolution testing. A comparative analysis of Fourier-transform infrared (FT-IR) spectra of pure polymers, acyclovir, and films containing polymers in different quantitative ratios was conducted. The quantitative ratio of chitosan to guar gum significantly impacted the mechanical properties of films: texture, elasticity, tensile strength, swelling, and blur time of the testes carriers. The 1:1 formulation showed the highest mechanical strength and flexibility. The dressing containing 1.2% chitosan and 0.5% guar gum had the longest blur time. An increase in the chitosan content in the formulation significantly affected the drug dissolution parameters, which makes it possible to achieve the desired effect of extended-release time. The FT-IR spectra excluded the formation of drug-polymer interactions. Changes in the quantitative ratios of chitosan and guar game in the carrier’s composition may impact the mechanical properties of the drug formulation and changes in the parameters of active substance release.